Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enmetazobactam
- Development stage
- Phase 3
- Lead developer
- Orchid Pharma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Enmetazobactam is a novel penicillanic acid sulfone beta-lactamase inhibitor structurally related to tazobactam. It is used in combination with cefepime, a fourth-generation cephalosporin, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in adults. Enmetazobactam works by inhibiting extended-spectrum beta-lactamases (ESBLs) and other class A beta-lactamases such as CTX-M, TEM, and SHV enzymes that confer resistance to many antibiotics. By blocking these enzymes, enmetazobactam protects cefepime from degradation and restores its antibacterial activity against ESBL-producing Enterobacterales and other resistant gram-negative bacteria. The combination has demonstrated superior efficacy compared to piperacillin/tazobactam in clinical trials and offers a carbapenem-sparing option for serious infections caused by multidrug-resistant organisms[2][5][7].
- Brand names
- Exblifep
- Other names
- cefepime + enmetazobactamcefepime/enmetazobactam
02
Targets
OXA (Class D beta-lactamase)AmpC (AmpC beta-lactamase)Neuraminidase
Beyond the preview
Go deeper on enmetazobactam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enmetazobactam.